NCT07570901

Brief Summary

Liver transplantation (LT) represents an important curative option for end stage liver disease such as decompensated cirrhosis, which remains a major challenge for today's health care system. The Model for End-Stage Liver Disease (MELD) is a worldwide-established scoring system for the evaluation of the severity of liver disease in allocation processes. However, the interpretation of MELD in clinical practice, particularly with regard to prioritizing potential liver transplant recipients, has revealed some hazards. These include the adaptation of MELD based on patient's characteristics, e.g. the presence of hepatocellular carcinoma, kidney failure and cardiovascular disease. In addition, the remaining paucity of organ donors contributes to a rising number of transplantations of high MELD recipients. This leads to the risk of impaired outcomes, especially considering the interaction of additional donor and recipient risk factors, such as extended cold preservation, kidney function and warm ischemia. For a certain patient cohort living donation might represent a feasible approach as reported previously for high MELD patients. Overall, the interaction of donor and recipient characteristics on the outcomes after LT in high MELD patients remains a scarcely investigated field. Therefore, the identification of factors influencing patient's outcomes after orthotopic liver transplantation becomes increasingly important, especially in high MELD recipients.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
446

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2010

Longer than P75 for all trials

Geographic Reach
2 countries

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
15 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

April 24, 2026

Completed
12 days until next milestone

First Posted

Study publicly available on registry

May 6, 2026

Completed
Last Updated

May 6, 2026

Status Verified

May 1, 2026

Enrollment Period

15 years

First QC Date

April 24, 2026

Last Update Submit

May 1, 2026

Conditions

Keywords

liver transplantationMELDdelta MELDpatient survivalliver allocation

Outcome Measures

Primary Outcomes (1)

  • overall mortality of LT recipients

    overall mortality of liver transplant recipients

    minimal follow up of 12 months up to fifteen years

Secondary Outcomes (1)

  • Perioperative lenght of intensive care unit (ICU) stay

    perioperative ICU stay, measured in days following liver transplantation maximal 24 weeks

Other Outcomes (1)

  • postoperative assessment of liver function

    laboratory values at routine follow-up appointments within 1 year following LT; usually at one, three, six and twelve months

Study Arms (2)

DMELD+

liver transplant recipients with a positive delta MELD

DMELD-

liver transplant recipients without delta MELD

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients who underwent LT between 2010 and 2025 who were listed with a high MELD at the time of LT ( above 30). LT-R who had a high change of MELD ( above 10 points within 30 days) were assigned to the DMELD+ group, LT recipients without this accelaration were assigned to the DMELD- group.

You may qualify if:

  • first LT
  • age above 18 years
  • completeness of dataset
  • liver only

You may not qualify if:

  • second or higher LT
  • age below 18 years
  • incomplete dataset
  • combined transplant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Toronto General Hospital

Toronto, Ontario, M5G 2C4, Canada

Location

Jena University Hospital

Jena, Thueringia, 07747, Germany

Location

MeSH Terms

Conditions

Liver Diseases

Condition Hierarchy (Ancestors)

Digestive System Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 24, 2026

First Posted

May 6, 2026

Study Start

January 1, 2010

Primary Completion

December 31, 2024

Study Completion

December 31, 2025

Last Updated

May 6, 2026

Record last verified: 2026-05

Locations